[Association of atrial fibrillation with hemorrhagic transformation after intravenous thrombolysis in patients with ischemic stroke]

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2019 May 25;48(3):254-259. doi: 10.3785/j.issn.1008-9292.2019.06.04.
[Article in Chinese]

Abstract

Objective: To investigate the association of atrial fibrillation (AF) with hemorrhagic transformation (HT) in patients with ischemic stroke treated by intravenous thrombolysis.

Methods: Clinical data of 3272 patients treated by intravenous thrombolysis from 71 hospitals in Zhejiang Province during June 2017 and December 2018 were retrospectively reviewed. Intracranial HT was defined as intracranial hemorrhage suggested by imaging examination 24 hours after intravenous thrombolysis. Patients were dichotomized into HT group (n=533) and non-HT group (n=2739). The association of AF and HT was analyzed by univariate analysis and binary logistic regression.

Results: Compared with the non-HT group, the HT group were older, had longer onset to needle time (ONT), higher baseline National Institute of Health Stroke Scale (NIHSS) score, higher baseline glucose level, and higher AF rate (P<0.05 or P<0.01). Binary logistic regression analysis revealed that AF was independently associated with HT (OR=2.527, 95%CI:2.030-3.146, P<0.01).

Conclusions: AF is independently associated with the occurrence of HT in ischemic stroke patients treated with intravenous thrombolysis.

目的: 分析合并心房颤动对缺血性脑卒中患者静脉溶栓后颅内出血转化的影响。

方法: 收集2017年6月至2018年12月浙江省71家医院3272例静脉溶栓患者的资料。静脉溶栓后24 h影像学检查提示颅内出血表现定义为颅内出血转化。根据患者是否出现出血转化分为出血转化组(533例)和未出血转化组(2739例),采用单因素和二元Logistic回归分析模型分析心房颤动是否与缺血性脑卒中患者静脉溶栓后出血转化相关。

结果: 出血转化组患者的年龄、起病至溶栓时间、基线美国国立卫生研究院卒中量表(NIHSS)评分、基线血糖水平、心房颤动患者比例高于未出血转化组( P < 0.05或 P < 0.01)。二元Logistic回归分析结果显示,心房颤动与缺血性脑卒中患者静脉溶栓后颅内出血转化的发生独立相关( OR=2.527,95% CI:2.030~3.146, P < 0.01)。

结论: 心房颤动与缺血性脑卒中患者静脉溶栓后出血转化增加相关。

MeSH terms

  • Antifibrinolytic Agents / adverse effects
  • Antifibrinolytic Agents / pharmacology
  • Atrial Fibrillation* / complications
  • Brain Ischemia* / complications
  • Brain Ischemia* / drug therapy
  • Humans
  • Retrospective Studies
  • Stroke* / complications
  • Stroke* / drug therapy
  • Thrombolytic Therapy / adverse effects
  • Treatment Outcome

Substances

  • Antifibrinolytic Agents

Grants and funding

浙江省重点研发计划(2018C04011);浙江省公益性技术应用研究计划(2016C33228)